Targeting a microbiota Wolbachian aminoacyl-tRNA synthetase to block its pathogenic host
Science Advances · 2024
DOI: 10.1126/sciadv.ado1453 ↗Kurz gefasst
Fachartikel in der Zeitschrift Science Advances, 2024. Verfasst von Guillaume Hoffmann und 10 weiteren Autor:innen. Beteiligte Einrichtung: Institute for Advanced Biosciences (IAB), Structural Biology of Novel Drug Targets in Human Diseases, INSERM U1209, CNRS UMR 5309, Université Grenobl…. Hauptthemen laut MEDLINE: Wolbachia, Microbiota. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 37 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
The interplay between humans and their microbiome is crucial for various physiological processes, including nutrient absorption, immune defense, and maintaining homeostasis. Microbiome alterations can directly contribute to diseases or heighten their likelihood. This relationship extends beyond humans; microbiota play vital roles in other organisms, including eukaryotic pathogens causing severe diseases. Notably, Wolbachia , a bacterial microbiota, is essential for parasitic worms responsible for lymphatic filariasis and onchocerciasis, devastating human illnesses. Given the lack of rapid cures for these infections and the limitations of current treatments, new drugs are imperative. Here, we disrupt Wolbachia ’s symbiosis with pathogens using boron-based compounds targeting an unprecedented Wolbachia enzyme, leucyl-tRNA synthetase (LeuRS), effectively inhibiting its growth. Through a compound demonstrating anti- Wolbachia efficacy in infected cells, we use biophysical experiments and x-ray crystallography to elucidate the mechanism behind Wolbachia LeuRS inhibition. We reveal that these compounds form adenosine-based adducts inhibiting protein synthesis. Overall, our study underscores the potential of disrupting key microbiota to control infections.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Institute for Advanced Biosciences (IAB), Structural Biology of Novel Drug Targets in Human Diseases, INSERM U1209, CNRS UMR 5309, Université Grenoble-Alpes, Grenoble 38000, France.
- Centre for Drugs and Diagnostics, Department of Tropical Disease Biology, Liverpool School of Tropical Medicine, Liverpool L3 5QA, UK.
- Université Grenoble Alpes, CEA, CNRS, IBS, Grenoble, France.
ORCID-Profile: Guillaume Hoffmann, Maria Lukarska, Rachel H Clare, Kelly L Johnston, Louise Ford, Joseph D Turner, Steve A Ward, Mark J Taylor, Malene Ringkjøbing Jensen, Andrés Palencia
Zitieren
APA
Hoffmann, G., Lukarska, M., Clare, R. H., Masters, E. K. G., Johnston, K. L., Ford, L., Turner, J. D., Ward, S. A., Taylor, M. J., Jensen, M. R., & Palencia, A. (2024). Targeting a microbiota Wolbachian aminoacyl-tRNA synthetase to block its pathogenic host. Science Advances. https://doi.org/10.1126/sciadv.ado1453
Vancouver
Hoffmann G, Lukarska M, Clare RH, Masters EKG, Johnston KL, Ford L, et al. Targeting a microbiota Wolbachian aminoacyl-tRNA synthetase to block its pathogenic host. Science Advances. 2024. doi:10.1126/sciadv.ado1453
BibTeX
@article{Hoffmann2024,
author = {Hoffmann, Guillaume and Lukarska, Maria and Clare, Rachel H and Masters, Ellen K G and Johnston, Kelly L and Ford, Louise and Turner, Joseph D and Ward, Steve A and Taylor, Mark J and Jensen, Malene Ringkjøbing and Palencia, Andrés},
title = {Targeting a microbiota Wolbachian aminoacyl-tRNA synthetase to block its pathogenic host},
journal = {Science Advances},
year = {2024},
doi = {10.1126/sciadv.ado1453}
}
EUVIMED